India needs affordable access alongside pharma innovation, experts say at OPPI summit

India's pharmaceutical sector is facing challenges in balancing innovation with affordable access to treatments. Experts believe that stronger partnerships and predictable policies are essential for fostering an innovative ecosystem. While high co...

India needs to strike a balance between encouraging pharmaceutical innovation and ensuring that breakthrough medicines reach patients at affordable prices, experts said at the Organisation of Pharmaceutical Producers of India (OPPI) Annual Summit on Thursday.

The discussion highlighted the challenges of building an innovation-driven pharmaceutical industry, with speakers calling for predictable regulatory policies, stronger intellectual property (IP) protection, regulatory data protection and greater collaboration between industry and academia. However, concerns were also raised that high-priced innovative therapies, particularly in cancer care that remain beyond the reach of most Indian patients.

Also Read: Centre proposes tighter regulatory oversight of antimicrobials to tackle drug resistance


Urvashi Prasad, former Director, Office of Vice Chairperson, NITI Aayog said access to cutting-edge therapies, particularly targeted therapies and immunotherapies for cancer, remained a major challenge. She pointed out that health insurance coverage had not kept pace with advances in treatment, with several oral cancer therapies not covered because patients were not necessarily hospitalised to receive them.

“An innovation is only as good as how many people can actually afford it and access it,” she said.

Also Read: India needs policy predictability to speed up drug approvals and boost pharma innovation: OPPI DG
ADVERTISEMENT

Citing the high out-of-pocket expenditure on healthcare in India, Prasad said some newer cancer treatments could cost Rs 40-50 lakh a month, putting them beyond the reach of the vast majority of patients. She called for the government to use its purchasing power to negotiate better prices, expand insurance coverage and widen access to clinical trials beyond large urban hospitals.

As a patient and patient advocate, she said several patients were forced to reduce doses, skip medication or resort to crowdfunding to continue treatment.

“Our lives are not cheaper, and so affordability is a very real issue,” she said, arguing that access to life-saving treatments could not be deferred by five or 10 years.

Shweta Rai, Managing Director, India and Country Division Head, South Asia, Pharmaceuticals Division, Bayer, highlighted the importance of partnerships in building the country’s innovation ecosystem.
ADVERTISEMENT

“Policy is the enabler, partnership is the multiplier,” she said, emphasising the need for collaboration between government, academia and industry.

Experts also stressed on the need for more predictable policy and regulatory environment in India to attract investments in pharmaceutical innovation.
ADVERTISEMENT

Krishna Sarma, Managing Partner, Corporate Law Group, said existing policy incentives appeared to be rooted in an older approach that largely viewed research and value creation through the public sector, whereas private investment and patient capital were equally important for building an innovation ecosystem.

She said predictability of policies in the pricing space is important. “Companies both Indian and foreign need to have at least a five-year plan for them to think of investing. There shouldn't be like a knee jerk changes in policy. So I think these are very important in terms of creating India as investment hub for innovation,” she said.

Experts also stated that initial three to five years after a new drug’s launch were important for generating safety and pharmacovigilance data and that India needed clinical exclusivity and regulatory data protection to encourage companies to invest in research and development (R&D).

Praveen Akkinepally, Country President and Managing Director, AstraZeneca Pharma India, said India had the scientific and medical talent, population diversity and digital capabilities needed to become a global R&D hub. However, strengthening regulatory pathways and providing stronger IP protection and regulatory data protection would be essential to attracting global investments.

Nikkhil K Masurkar, CEO and Head of Global Innovation at Entod Pharmaceuticals, said India needed to bridge a significant innovation gap. Since 2021, the US had introduced more than 500 indigenous new formulations, drugs and new chemical entities, while China had introduced around 150 and India only eight to 10, he said.

He said artificial intelligence (AI) could accelerate pharmaceutical research by helping identify new therapeutic targets, repurpose existing drugs and develop treatments for diseases particularly prevalent in India.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Industry › Healthcare/Biotech › Pharmaceuticals › India needs affordable access alongside pharma innovation, experts say at OPPI summit
Text Size:AAA
Success
This article has been saved

*

+